Literature DB >> 15004154

Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function.

Daohong Chen1, Hideki Iijima, Takashi Nagaishi, Atsushi Nakajima, Sara Russell, Raktima Raychowdhury, Victor Morales, Christopher E Rudd, Nalan Utku, Richard S Blumberg.   

Abstract

Carcinoembryonic Ag-related cellular adhesion molecule 1 (CEACAM1) represents a group of transmembrane protein isoforms that consist of variable numbers of extracellular Ig-like domains together with either a long cytoplasmic (cyt) tail containing two immunoreceptor tyrosine-based inhibitory motifs or a unique short cyt tail. Although CEACAM1 has been reported to be expressed on the surface of T lymphocytes upon activation, its roles in T cell regulation are controversial due to the lack of functional characterization of each individual CEACAM1 isoform. We thus cotransfected Jurkat T cells with CEACAM1 isoform-encoding constructs and an IL-2 promoter-bearing plasmid or a small interference RNA targeting src homology domain 2 containing phosphatase 1. In a luciferase reporter assay and through measurements of cytokine secretion (IL-2, IL-4, and IFN-gamma), CEACAM1 containing either a long or a short cyt tail inhibited or costimulated, respectively, TCR/CD3 complex plus CD28 mediated activation with the inhibitory functions of the long cyt tail dominating. The inhibitory function of CEACAM1, was dependent upon src homology domain 2 containing phosphatase 1 activity, required both tyrosine residues within the immunoreceptor tyrosine-based inhibitory motif domains of the cyt tail and was mediated through the mitogen-activated protein kinase pathway. CEACAM1-mediated inhibition could be functionally reconstituted by incubation of PBMC with either a CEACAM1-specific mAb or CEACAM1-Fc fusion protein in the presence of an allogeneic or mitogenic stimulus, respectively. These studies indicate that the long and short cyt tails of CEACAM1 serve as inhibitory and costimulatory receptors, respectively, in T cell regulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004154     DOI: 10.4049/jimmunol.172.6.3535

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Authors:  Yu-Hwa Huang; Chen Zhu; Yasuyuki Kondo; Ana C Anderson; Amit Gandhi; Andrew Russell; Stephanie K Dougan; Britt-Sabina Petersen; Espen Melum; Thomas Pertel; Kiera L Clayton; Monika Raab; Qiang Chen; Nicole Beauchemin; Paul J Yazaki; Michal Pyzik; Mario A Ostrowski; Jonathan N Glickman; Christopher E Rudd; Hidde L Ploegh; Andre Franke; Gregory A Petsko; Vijay K Kuchroo; Richard S Blumberg
Journal:  Nature       Date:  2014-10-26       Impact factor: 49.962

2.  CEACAM1 regulates CD8+ T cell immunity and protects from severe pathology during Citrobacter rodentium induced colitis.

Authors:  Julia Zöller; Jana-Fabienne Ebel; Vishal Khairnar; Verena Schmitt; Robert Klopfleisch; Jana Meiners; Virginia Seiffart; Wiebke Hansen; Jan Buer; Bernhard B Singer; Karl S Lang; Astrid M Westendorf
Journal:  Gut Microbes       Date:  2020-06-10

3.  Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling.

Authors:  Ning Wang; Zhe Li; Ronghua Ding; Gerald D Frank; Takaaki Senbonmatsu; Erwin J Landon; Tadashi Inagami; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2006-06-08       Impact factor: 5.157

4.  Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells.

Authors:  Ngozi Monu; Alan B Frey
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

5.  Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner.

Authors:  Elizabeth O Lobo; Zhifang Zhang; John E Shively
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

Review 6.  CEACAM1 and the regulation of mucosal inflammation.

Authors:  T Nagaishi; Z Chen; L Chen; H Iijima; A Nakajima; R S Blumberg
Journal:  Mucosal Immunol       Date:  2008-11       Impact factor: 7.313

7.  Mutational analysis of the cytoplasmic domain of CEACAM1-4L in humanized mammary glands reveals key residues involved in lumen formation: stimulation by Thr-457 and inhibition by Ser-461.

Authors:  Chunxia Li; Charng-Jui Chen; John E Shively
Journal:  Exp Cell Res       Date:  2008-12-30       Impact factor: 3.905

Review 8.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

9.  Serum carcinoembryonic antigen-related cell adhesion molecule 1 level in postmenopausal women: correlation with β-catenin and bone mineral density.

Authors:  C Ma; B Shuai; L Shen; Y P Yang; X J Xu; C G Li
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

10.  Perturbation of lytic and latent gammaherpesvirus infection in the absence of the inhibitory receptor CEACAM1.

Authors:  Heiko Adler; Susanne El-Gogo; Simone Guggemoos; Wolfgang Zimmermann; Nicole Beauchemin; Robert Kammerer
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.